創元科技(000551.SZ):子公司預中標1.52億元國家電網採購項目
格隆匯4月8日丨創元科技(000551.SZ)宣佈,2021年04月06日,國家電網通過其電子商務平台發佈了“國家電網2021年特高壓工程第十二批採購(白鶴灘-江蘇第三次物資招標採購)推薦的中標候選人公示”。公司控股子公司蘇州電瓷廠股份有限公司(簡稱“蘇州電瓷”)為推薦中標候選人。
根據公示,蘇州電瓷為國家電網2021年特高壓工程第十二批採購(白鶴灘-江蘇第三次物資招標採購)~絕緣子包8的推薦中標候選人(招標項目編號:0711-21OTL03021004),預中標瓷絕緣子37萬餘隻,預中標金額約1.52億元(含税),佔公司2020年度營業收入的4.75%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.